Long-term follow-up of patients with iron deficiency anemia after a close endoscopic examination of the upper and lower gastrointestinal tract

2000 ◽  
Vol 38 (10) ◽  
pp. 827-832 ◽  
Author(s):  
D Schilling ◽  
G Grieger ◽  
E Weidmann ◽  
H E Adamek ◽  
C Benz ◽  
...  
Keyword(s):  
Gastrointestinal Tract ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Endoscopic Examination ◽  
Deficiency Anemia ◽  
Lower Gastrointestinal Tract ◽  
Long Term Follow Up

Long-Term Follow-Up and Predictive Factors of Recurrence of Anemia in a Cohort of 102 Very Elderly Patients Explored for Iron Deficiency Anemia

2007 ◽  
Vol 65 (5) ◽  
pp. AB270
Author(s):  
Stéphane Nahon ◽  
Pierre Lahmek ◽  
Francine Barclay ◽  
Gilles Macaigne ◽  
Cécile Poupardin ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Elderly Patients ◽  
Iron Deficiency Anemia ◽  
Predictive Factors ◽  
Deficiency Anemia ◽  
Very Elderly ◽  
Long Term Follow Up

Long term results of the use of compression anastomosis clips (CAC) in gastrointestinal surgery – the first report

2015 ◽  
Vol 87 (6) ◽  
Author(s):  
Katarzyna Kuśnierz ◽  
Paweł Lampe
Keyword(s):  
Gastrointestinal Tract ◽  
Gastrointestinal Surgery ◽  
Endoscopic Examination ◽  
Long Term Results ◽  
Lower Gastrointestinal Tract ◽  
Compression Anastomosis ◽  
Discharge From Hospital ◽  
Braun Enteroenterostomy

AbstractThe aim of the study was to present the first long-term results on the clinical use of compression anastomosis clips (CAC) in upper and lower gastrointestinal tract anastomoses.Material and methods. The study included 50 patients who underwent anastomosis of the upper (n = 32) or lower GI tract (n = 18) with the use of CAC. In the period of 6‑7 months after the surgery, patients underwent endoscopic examination and computed tomography evaluation of the anastomosis. Each anastomosis was evaluated macro and microscopically. The width of anastomoses was evaluated using a 4-point-scale for grading stenosis.Results. Of the 50 patients who underwent anastomosis with compression anastomosis clip, 28 (56%) patients reported to the follow-up examination within 190‑209 days of the execution of the anastomosis. Among the 22 patients who did not report to the study, 18 (36%) patients died within 91‑154 days from the execution of the anastomosis (mean 122 days), 4 (8%) patients were impossible to contact after discharge from hospital. Two mild stenoses (I0) were diagnosed; 1 of them was found in the gastroenterostomy and 1 in Braun enteroenterostomy. Microscopic changes were diagnosed in 4 anastomoses (3 gastroenterostomies, 1 Braun enteroenterostomy). Anastomoses were well-formed and wide, scars in the line of anastomoses were thin.Conclusions. During the period of 6 months after the anastomoses performed using CAC have been formed, they were evaluated as unobstructed and functioning properly; therefore, they can be safely performed within the upper and lower gastrointestinal tract.

scholarly journals Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial

2021 ◽  
Author(s):  
Stefanie Howaldt ◽  
Eugeni Domènech ◽  
Nicholas Martinez ◽  
Carsten Schmidt ◽  
Bernd Bokemeyer
Keyword(s):  
Inflammatory Bowel Disease ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Primary Endpoint ◽  
Bowel Disease ◽  
Deficiency Anemia ◽  
Ferric Carboxymaltose ◽  
Inflammatory Bowel ◽  
Intent To Treat

Abstract Background Iron-deficiency anemia is common in inflammatory bowel disease, requiring oral or intravenous iron replacement therapy. Treatment with standard oral irons is limited by poor absorption and gastrointestinal toxicity. Ferric maltol is an oral iron designed for improved absorption and tolerability. Methods In this open-label, phase 3b trial (EudraCT 2015-002496-26 and NCT02680756), adults with nonseverely active inflammatory bowel disease and iron-deficiency anemia (hemoglobin, 8.0-11.0/12.0 g/dL [women/men]; ferritin, <30 ng/mL/<100 ng/mL with transferrin saturation <20%) were randomized to oral ferric maltol 30 mg twice daily or intravenous ferric carboxymaltose given according to each center’s standard practice. The primary endpoint was a hemoglobin responder rate (≥2 g/dL increase or normalization) at week 12, with a 20% noninferiority limit in the intent-to-treat and per-protocol populations. Results For the intent-to-treat (ferric maltol, n = 125/ferric carboxymaltose, n = 125) and per-protocol (n = 78/88) analyses, week 12 responder rates were 67% and 68%, respectively, for ferric maltol vs 84% and 85%, respectively, for ferric carboxymaltose. As the confidence intervals crossed the noninferiority margin, the primary endpoint was not met. Mean hemoglobin increases at weeks 12, 24, and 52 were 2.5 vs 3.0 g/dL, 2.9 vs 2.8 g/dL, and 2.7 vs 2.8 g/dL with ferric maltol vs ferric carboxymaltose. Treatment-emergent adverse events occurred in 59% and 36% of patients, respectively, and resulted in treatment discontinuation in 10% and 3% of patients, respectively. Conclusions Ferric maltol achieved clinically relevant increases in hemoglobin but did not show noninferiority vs ferric carboxymaltose at week 12. Both treatments had comparable long-term effectiveness for hemoglobin and ferritin over 52 weeks and were well tolerated.

Sign in / Sign up

Export Citation Format

Share Document